ArticleThe Pediatric infectious disease journal2025
Examining Neutropenia During Treatment of Cytomegalovirus Disease in Neonates.
Article in The Pediatric infectious disease journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Current status of primary, secondary and tertiary prevention of congenital cytomegalovirus disease: a call to action.Current opinion in infectious diseases · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCongenital cytomegalovirus is the leading cause of nongenetic sensorineural hearing loss. Treatment with (val)ganciclovir improves audiologic outcomes. Neutropenia is a common adverse event, but correlates that predict who will develop neutropenia have not been identified.
methodsData from 3 National Institutes of Health-funded studies of intravenous ganciclovir or oral valganciclovir were evaluated. Baseline absolute neutrophil count (ANC) was defined as high (ANC >1000 cells/mm 3 ) or low (ANC ≤1000 cells/mm 3 ), and neutropenia was defined as ANC <800 cells/mm 3 . Mean 12-hour area under the curve (AUC 12 ) ganciclovir values were analyzed as a function of degree of neutropenia using analysis of variance. AUC 12 values ≥40 mgxhr/L were defined as high drug exposure and <40 mgxhr/L as low drug exposure.
resultsOf 134 subjects who had AUC 12 values obtained during the first week of treatment, 61 (46%) developed neutropenia <800 cells/mm 3 . Infants with high drug exposure developed neutropenia more rapidly than subjects with low drug exposure (median of 28 vs. 216 days; P < 0.008). Although not significant, infants with a baseline ANC ≤1000 cells/mm 3 were observed to develop neutropenia more rapidly compared with those with a high baseline ANC (estimated median of 69 vs. 216 days; P = 0.22) and in greater proportions, although not statistically significant [55.6% vs. 39.3%; P = 0.21; odds ratio, 1.9 (95% CI, 0.71-5.20)].
conclusionsHigh AUC 12 correlated with the development of neutropenia in infants treated for symptomatic congenital cytomegalovirus disease. Low baseline ANC also may contribute to the development of neutropenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.